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Background: In patients with relapsing–remitting multiple sclerosis (RRMS), subcutaneous (sc) interferon (IFN)β-1a
and IFNβ-1b have been shown to reduce relapse rates. A formulation of IFNβ-1a has been produced without
fetal bovine serum and without human serum albumin as an excipient (not currently approved for use in the US).
The objectives of this study were to evaluate tolerability, injection-site redness, subject-reported satisfaction with
therapy, and clinical safety and efficacy of the serum-free formulation of IFNβ-1a versus IFNβ-1b in
IFNβ-treatment-naïve patients with RRMS. The objectives of the extension phase were to evaluate long-term safety
and tolerability of IFNβ-1a.
Methods: This randomized, parallel-group, open-label study was conducted at 27 clinical sites in the US. Eligible
patients aged 18–60 years were randomized to receive either IFNβ-1a, titrated to 44 μg sc three times weekly
(tiw) (n = 65), or IFNβ-1b, titrated to 250 μg sc every other day (n = 64) over 12 weeks. Following this, all patients
received IFNβ-1a 44 μg tiw for 82–112 weeks. Primary endpoint was mean change in patient-reported pain, as
assessed by visual analog scale (VAS) diary pain score (from 0 mm [no pain] to 100 mm [worst possible pain]) at
the injection site, from pre-injection to 30 min post-injection over the first 21 full-dose injections. Secondary
assessments included proportion of patients pain-free as recorded by VAS diary and the Short-Form McGill Pain
questionnaire VAS.
Results: A total of 129 patients were included in the intent-to-treat analysis. Mean (standard deviation) change in
VAS diary pain score was not significantly different between groups, although numerically lower with IFNβ-1a
versus IFNβ-1b from pre-injection to immediately post-injection (1.46 [2.93] vs. 4.63 [10.57] mm), 10 min
post-injection (0.70 [1.89] vs. 1.89 [5.75] mm), and 30 min post-injection (0.67 [2.32] vs. 1.14 [4.94] mm). Proportion
of patients pain-free at all time periods post-injection was also not significantly different between groups. Adverse
events were consistent with the known safety profiles of these treatments.
Conclusions: In IFNβ-treatment-naïve patients with RRMS, both the serum-free formulation of IFNβ-1a and IFNβ-1b
treatments were generally accompanied by low-level injection-site pain and were well tolerated.
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Clinical studies of subcutaneous (sc) interferon (IFN)β-1a
and IFNβ-1b have shown that these disease-modifying
drugs reduce relapse rates in patients with relapsing–
remitting multiple sclerosis (RRMS) [1-4]. At the doses
approved for the treatment of RRMS, both IFNβ-1a and
IFNβ-1b have established long-term safety and tolerability
profiles [5,6]. However, injections with these drugs are
commonly associated with injection-site reactions (ISRs),
injection-site pain, and flu-like symptoms (FLS), which can
lead to poor adherence to treatment in some patients [7,8].
A formulation of IFNβ-1a has been developed without
fetal bovine serum and without human serum albumin
as an excipient, although this formulation is not cur-
rently approved for use within the US. In a 96-week
study in patients with relapsing MS, the serum-free for-
mulation of IFNβ-1a was associated with a lower preva-
lence of ISRs than had been seen in two earlier studies
with the original IFNβ-1a formulation [9-11]. No rando-
mized clinical study has yet compared the injection-site
pain and tolerability profile of the serum-free formulation
IFNβ-1a with that of another disease-modifying drug.
The primary objective of this study was to compare
the tolerability of the serum-free formulation of IFNβ-
1a, 44 μg sc three times weekly (tiw), with IFNβ-1b,
250 μg sc every other day (qod), as measured by the
mean change in subject-reported injection-site pain
from pre-injection to 30 min post-injection in IFNβ-
treatment-naïve patients with RRMS during a 12-week
period (comparative phase). During the extension phase,
the primary objective was to evaluate long-term safety
and tolerability of IFNβ-1a sc tiw.
Secondary efficacy endpoints included: the mean
difference in injection-site pain from pre-injection to
immediately post-injection and to 10 min post-injection,
the proportion of pain-free patients, number and severity
of relapses, assessments of the treatment of side effects,
patient-rated treatment satisfaction, and rater-blinded
assessment of injection-site redness.
Safety endpoints included analysis of adverse events
(AEs), laboratory tests, physical examinations, vital signs,
and concomitant medications.Methods
Study design and patients
The Rebif New Formulation Versus Betaseron Toler-
ability Study (REFORMS) (ClinicalTrials.gov identifier:NCT00428584) was a randomized, multicenter, 2-arm,
Phase IIIb study conducted at 27 clinical sites in the US.
The study consisted of a 12-week randomized compara-
tive phase, which was followed by a safety-extension
phase of up to 112 weeks (range 82–112 weeks). The
study was open-label, except for blinded assessments of
ISRs. The initial central Institutional Review Board (IRB)
submission was approved by Coast IRB, Colorado
Springs, Colorado and, later, Schulman Associates IRB,
Cincinnati, Ohio. For those sites that were not permitted
to use a central IRB for study approval, submissions
were made to the local IRB. This study was performed
in accordance with the study protocol, the Declaration
of Helsinki, the International Conference on Harmoni-
zation (ICH) Harmonized Tripartite Guideline for Good
Clinical Practice (GCP), and all applicable regulatory
requirements. Patients provided written informed con-
sent for participation in the study.
Eligible patients were 18–60 years of age, had a pri-
mary diagnosis of RRMS as defined by the Poser or 2005
revised McDonald criteria [12,13], and had not previ-
ously received IFNβ treatment. Patients were not eligible
if they had used any other approved disease-modifying
treatment for MS (e.g. glatiramer acetate) or any cyto-
kine or anti-cytokine treatment within 3 months before
study initiation, used any immunomodulatory or im-
munosuppressive treatment within 12 months before
study initiation, used any investigational drug or experi-
mental procedure within 12 weeks before screening,
received oral or systemic corticosteroids or adrenocorti-
cotropic hormone within 30 days of study initiation, or
used other injectable medications on a regular basis dur-
ing the week before screening. Other exclusion criteria
included having an alternative diagnosis to RRMS and
being pregnant or breastfeeding. Women of childbearing
potential were required to use appropriate contracep-
tion. All patients provided written informed consent.Treatments
Patients were randomized 1:1 to receive either the
serum-free formulation of IFNβ-1a 44 μg sc tiw or
IFNβ-1b 250 μg sc qod for the 12 weeks of the compara-
tive phase. Treatments were allocated using a computer-
generated randomization code. The doses of IFNβ-1a
and IFNβ-1b were up-titrated at the beginning of the
study according to the US prescribing information for
each drug (Figure 1) [14,15]. Following the 12-week
Figure 1 Titration schedules for subcutaneous IFNβ-1a and IFNβ-1b. The first 21 injections of full-dose IFNβ-1a and IFNβ-1b treatment were
termed the “full-dose period”. IFN, interferon; qod, every other day; tiw, three times weekly.
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formulation of IFNβ-1a 44 μg sc tiw during the safety-
extension phase. Patients who transitioned from IFNβ-
1b to IFNβ-1a could be up-titrated to the full dose of
IFNβ-1a at the discretion of the investigator. Patients
who did not wish to transition from IFNβ-1b to IFNβ-1a
were withdrawn from the study. The length of the exten-
sion phase varied between 82 and 112 weeks, depending
on the patient’s date of enrollment. The extension phase
ended within 14 days of when the last enrolled patient
completed the last visit at Week 94.
All patients self-administered IFNβ using the Rebi-
ject IIW autoinjector (EMD Serono, Inc., Rockland, MA,
USA) with a 29-gauge needle for IFNβ-1a or BetajectW
(with a 27-gauge needle), Betaject LiteW (with a 30-
gauge needle), or BetajectW 3 (with a 27-gauge needle)
(Bayer HealthCare Pharmaceuticals Inc., Montville, NJ,
USA). Acetaminophen was given prophylactically at the
discretion of the treating physician and dosed as needed
to ameliorate constitutional symptoms (e.g. fever, myal-
gia, and FLS). Nonsteroidal anti-inflammatory drugs
were given and dosed as needed at the discretion of the
treating physician if acetaminophen failed to alleviate
or prevent constitutional symptoms or if patients were
allergic to, or unable to tolerate, acetaminophen.
Assessments
Patient-reported pain was evaluated in a visual analog
scale (VAS) diary and the Short-Form McGill Pain
Questionnaire (SF-MPQ) [16]. Patients used the VAS
diary to record the level of pain on a scale from 0 mm
(no pain) to 100 mm (worst possible pain), immediately
before, immediately after, 10 min after, and 30 min after
the injection. The SF-MPQ also included a VAS for
patients to record the level of the maximum amount of
pain experienced during the 60 min after injection, from
0 mm (no pain) to 100 mm (worst possible pain). In
addition, patients were requested to describe the types
of pain that they experienced during the 60 min afterinjection. Patients completed the VAS diary and the SF-
MPQ after every injection during the comparative phase
and for the first 4 weeks of the safety-extension phase.
The Multiple Sclerosis Treatment Satisfaction Ques-
tionnaire (MSTSQ) adapted from Cramer et al. [17]
included patient assessments of mood, treatment satis-
faction, FLS, and ISRs. The MSTSQ was issued to
patients at Weeks 2, 4, 6, 8, 12, 16, 24, 36, and 48. Mean
values are reported for each treatment phase.
ISRs were assessed at each visit during the first
48 weeks by a healthcare professional who was blinded
to treatment assignment. ISR measures included the
diameter of injection-site redness, injection-site swelling,
bruising, and consideration of patient-reported itching,
within 72 h of the most recent injection.
Compliance was recorded throughout the study and
was defined as the actual number of injections divided
by the expected number of injections, expressed as a
percentage. Safety assessments included AEs (coded
to system organ class and preferred term using the
MedDRA dictionary [Version 9.1] and summarized by
severity and relationship), vital signs, hematology, and
serum chemistry. Analgesic use among patients with
and without AEs related to FLS was summarized by
treatment group during the comparative phase and by
treatment group and overall population during the
extension phase.
The primary endpoint was the mean change in the
VAS diary pain score from pre-injection to 30 min post-
injection over the first 21 injections of full-dose IFNβ-1a
and IFNβ-1b treatment (“full-dose period”). Due to the
different titration schedules and dose frequencies of each
treatment, the first 21 full-dose injections were adminis-
tered during Weeks 5–11 in the IFNβ-1a group and
during Weeks 7–12 in the IFNβ-1b group (Figure 1).
Secondary endpoints included mean changes in the VAS
diary pain score from pre-injection to immediately post-
injection and 10 min post-injection; MSTSQ assess-
ments; rater-blinded assessment of the mean diameter of
Singer et al. BMC Neurology 2012, 12:154 Page 4 of 11
http://www.biomedcentral.com/1471-2377/12/154injection-site redness; and SF-MPQ assessments, includ-
ing the proportion of patients pain-free as recorded on
the SF-MPQ VAS. Types of pain and severity experi-
enced by the patient were also recorded on the SF-MPQ.
The number of relapses and severity were secondary effi-
cacy endpoints. Relapses were patient-reported and not
objectively assessed; the number and severity of relapses
were observational clinical assessments.
Statistical analysis
The primary analysis population was the intent-to-treat
population (all patients randomized to treatment). The
safety population consisted of all patients who received
at least one injection of study drug. The safety-extension
population consisted of all patients who received at
least one injection of study drug and had available exten-
sion phase data. Baseline characteristics of the two treat-
ment groups were compared using analysis of variance
(ANOVA) with effects for treatment group and pooled
site for continuous variables and the Cochran–Mantel–
Haenszel general association test, adjusted for pooled
site, for categorical variables.
The null hypothesis was that there would be no differ-
ence in mean change in VAS pain score at 30 min post-
injection from pre-injection across the treatments at
full dose. The primary endpoint was evaluated with a
two-way ANOVA model on signed ranked data, includ-
ing treatment group and pooled site as main effects. The
same method was also used to analyze treatment com-
parisons of the mean changes in the VAS diary pain
score from pre-injection to immediately post-injection
and 10 min post-injection, as well as mean SF-MPQ
pain score at 60 min post-injection. An ANOVA model
was used for between-group comparisons; for MSTQ
scores, treatment group and pooled site were main
effects; for injection-site redness, treatment group and
site were main effects. The proportion of patients pain-
free on SF-MPQ VAS was analyzed using the Cochran–
Mantel–Haenszel general association test, adjusted for
site, or Fisher’s exact test, if appropriate. Injection-site
swelling, bruising, and itching were compared between
groups using a Cochran–Armitage trend test. In the
comparative phase, all statistical tests were two-sided
and used a significance level of α = 0.05. No adjustment
was made for multiple comparisons.
Patient-reported relapses during the comparative
phase were compared using a Poisson regression model
with the total number of relapses as the dependent vari-
able and treatment group and pooled site as independ-
ent variables.
Determination of sample size
A total of 100 patients (50 per arm) was calculated to
provide at least 90% power to detect the differencebetween treatment groups for the primary objective,
when the expected treatment effect size (the difference
between the treatment groups divided by the standard
deviation [SD]) was at least 0.735. The effect size was
based on a difference between the treatment groups of
0.025 mm and an SD value of 0.034 mm. The difference
between the treatment groups was based on a mean
change of 0.1 mm in the IFNβ-1a group and 0.125 mm
in the IFNβ-1b group, and assumed that the mean VAS
diary pain scores at pre-injection in the two treatment
groups were similar. The calculation also assumed a
two-sided Wilcoxon rank sum test, a common SD of
the change of ≤0.034 mm, and a Type I error rate of 5%.
Results
Patient disposition and baseline characteristics
Between May 2006 and July 2009, a total of 129 patients
were enrolled: 65 were randomized to IFNβ-1a and
64 to IFNβ-1b (Figure 2). Patient baseline characteristics
(Table 1) did not differ significantly between groups.
Fifty-six patients in the IFNβ-1a group completed the
comparative phase and entered the safety-extension
phase, and these were termed the “Always IFNβ-1a”
group (Figure 2). Of the 63 patients in the IFNβ-1b
group who completed the comparative phase, 60 entered
the extension phase and were termed the “Delayed
IFNβ-1a” group. During the extension phase, the mean
(SD) duration of treatment with IFNβ-1a was longer in
the Always IFNβ-1a group (436 [251] days) than in the
Delayed IFNβ-1a group (338 [260] days).
Tolerability
Comparative phase
During the full-dose period, the VAS diary pain score
was very low across both treatments. Mean changes in
pain scores from pre-injection to immediately, 10 min,
and 30 min after injection were all <5 mm with both
treatments (Figure 3). The mean (SD) pre-injection VAS
diary pain score was 0.43 (2.06) mm in the IFNβ-1a
group and 0.40 (1.64) mm in the IFNβ-1b group. The
primary endpoint of mean change in the VAS diary
pain score from pre-injection to 30 min post-injection
during the full-dose period was not statistically different
between IFNβ-1a and IFNβ-1b (mean [SD] 0.67 [2.32]
mm vs. 1.14 [4.94] mm, respectively, p = 0.524; Figure 3)
but was numerically lower with IFNβ-1a than with
IFNβ-1b. Mean changes in the VAS diary pain score
from pre-injection to immediately and 10 min post-
injection during the full-dose period were also not statis-
tically different across groups (Figure 3).
The proportions of patients who were pain-free on the
VAS diary during the full-dose period (score of 0 mm
for all full-dose injections) immediately, 10 min, and
30 min after injection were not statistically different
16 were excluded
11 did not meet eligibility criteria
5 other reasons (withdrew consent, lost 
to follow-up, laboratory findings)
26 discontinued treatment
9 adverse events
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Figure 2 Patient enrollment and disposition. IFN, interferon; ITT, intent-to-treat; qod, every other day; sc, subcutaneous; tiw, three
times weekly.
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IFNβ-1a than with IFNβ-1b (Figure 4). The mean SF-
MPQ VAS pain scores were similar between the two
groups, as were the proportions of patients who were
pain-free on the SF-MPQ VAS (Table 2). During the
full-dose period, the most common types of pain experi-
enced during the 60 min after injection (incidence of
≥20% in either group) were hot-burning (reported by
40.0% of patients in the IFNβ-1a group vs. 53.1% of
patients in the IFNβ-1b group), aching (29.2% vs. 45.3%),
sharp (35.4% vs. 42.2%), tender (33.8% vs. 35.9%), shoot-
ing (26.2% vs. 34.4%), stabbing (29.2% vs. 32.8%), throb-
bing (27.7% vs. 32.8%), and heavy (9.2% vs. 23.4%).The proportion of patients who reported any occur-
rence of FLS during the entire 12-week comparative
phase on the MSTSQ was 84.6% with IFNβ-1a and
93.8% for IFNβ-1b; for the titration period, the occur-
rence of FLS was 75.4% and 87.5% with IFNβ-1a and
IFNβ-1b, respectively. For the full-dose period, the FLS
score was 84.6% and 76.6% with IFNβ-1a versus IFNβ-
1b, respectively. The difference in frequency of FLS be-
tween IFNβ-1a (mean 3.55; SD 1.45) and IFNβ-1b (mean
2.78; SD 1.4) was significant (p = 0.003). The ratio of the
percentage of patients reporting ISRs on the MSTQ dur-
ing the full-dose period was similar to that of the FLS
score. The difference in frequency of ISRs between
Table 1 Baseline characteristics of patients (intent-to-treat population) randomized to receive subcutaneous IFNβ-1a or
IFNβ-1b
Baseline characteristic IFNβ-1a (N = 65) IFNβ-1b (N = 64)
Age, years
Mean (SD) 40.26 (9.80) 40.78 (9.56)
Median (range) 40.0 (20–60) 40.0 (19–59)
Female, n (%) 46 (70.8) 44 (68.8)
Race, n (%)
White 55 (84.6) 58 (90.6)
Black 6 (9.2) 5 (7.8)
Asian 2 (3.1) 0
Other 2 (3.1) 1 (1.6)
BMI, kg/m2, mean (SD) 29.66 (6.76) 30.23 (8.35)
Classification of MS, n (%)
Poser criteria 19 (29.2) 17 (26.6)
McDonald criteria 46 (70.8) 47 (73.4)
Time since first signs and/or symptoms of MS (onset), years, mean (SD) 4.51 (6.70) 5.74 (6.66)
Time since MS diagnosis, years, mean (SD) 1.01 (2.35) 1.93 (4.02)
Patients with no relapse during the 12 months before informed consent, n (%) 10 (15.4) 14 (21.9)
Relapses per patient,a mean (SD) 1.36 (0.52) 1.30 (0.46)
Time since last relapse,a months, mean (SD) 3.52 (2.94) 4.01 (2.93)
Number of steroid courses required for relapses per patient,a mean (SD) 0.53 (0.60) 0.46 (0.50)
Patients who required ≥1 course of steroids,a n (%) 26 (47.3) 23 (46.0)
aBased on total number of patients with relapses during the 12 months before informed consent.
BMI, body mass index; IFN, interferon; MS, multiple sclerosis; SD, standard deviation.
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SD 1.45) was significant (p = 0.005). The mean MSTSQ
scores for overall satisfaction, injection system, and
background information were similar between the two
groups during the full-dose period (Table 2).
Blinded assessment of ISRs during the full-dose period
found that the diameter of injection-site redness was simi-
lar between the two groups (Table 2). The proportions ofFigure 3 Mean change in VAS diary pain score during full-dose
treatment in the comparative phase (intent-to-treat
population). The VAS ranged from 0 mm (no pain) to 100 mm
(worst possible pain). The mean change was calculated from the
mean of 21 full-dose injections for each patient. IFN, interferon; SD,
standard deviation; VAS, visual analog scale.patients with injection-site swelling and itching were
similar between the two groups, but the incidence of
injection-site swelling was significantly greater with
IFNβ-1b than with IFNβ-1a during the uptitration period
(28.1% vs. 18.5%, respectively; p = 0.042). Injection-site
bruising was significantly more common with IFNβ-1aFigure 4 Patients who reported as pain-free on the VAS diary
in the comparative phase (intent-to-treat population). Pain-free
was defined as a VAS diary pain score of 0 mm (on a scale from
0 [no pain] to 100 mm [worst possible pain]) for all 21 full-dose
injections. IFN, interferon; VAS, visual analog scale.
Table 2 MSTSQ, ISR, and SF-MPQ endpoints during the full-dose period of the comparative phase (intent-to-treat
population)
IFNβ-1a (N = 65) IFNβ-1b (N = 64) p-value
MSTSQ assessments
MSTSQ overall satisfaction score,a mean (SD) 1.51 (0.56) 1.53 (0.63) 0.616
MSTSQ injection system score,a mean (SD) 1.68 (0.41) 1.80 (0.45) 0.156
MSTSQ score for background information,a mean (SD) 2.28 (0.91) 2.28 (0.86) 0.734
Blinded assessment of ISRs
Diameter of injection-site redness, mm, mean (SD) 11.32 (14.88) 11.75 (15.53) 0.986
Patients, n (%), with:
Injection-site swelling 19 (29.2) 16 (25.0) 0.848
Injection-site bruising 21 (32.3) 7 (10.9) 0.019
Injection-site itching 7 (10.8) 6 (9.4) 0.366
SF-MPQ assessments
SF-MPQ VAS pain score,b mm, mean (SD) 2.54 (7.98) 3.24 (8.78) 0.612
Patients pain-free on SF-MPQ VAS,b,c n (%) 17 (26.2) 17 (26.6) 0.852
aOn the MSTSQ, a lower score indicates a more favorable response to treatment. bThe SF-MPQ VAS recorded the maximum amount of pain experienced during
the 60 min after injection, from 0 mm (no pain) to 100 mm (worst possible pain). cPain-free was defined as an SF-MPQ VAS score of 0 mm.
IFN, interferon; ISR, injection-site reaction; MSTSQ, Multiple Sclerosis Treatment Satisfaction Questionnaire; SD, standard deviation; SF-MPQ, Short-Form McGill Pain
Questionnaire; VAS, visual analog scale.
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comparative phase (32.3% vs. 10.9%, respectively; p =
0.019) (Table 2). However, most incidents were mild
in severity.
Safety-extension phase
During the first 4 weeks of the safety-extension phase,
the mean changes in VAS diary pain scores from before
injection to all timepoints after injection were all <3 mm
in both the Always and Delayed IFNβ-1a groups. More
than half of all patients were pain-free on the VAS diary
10 min after injection. MSTSQ assessments for FLS,
overall satisfaction, injection system background infor-
mation, and ISRs were similar in the Always and
Delayed groups, although blinded assessment of ISRs
were numerically lower (7.46 mm) for the Delayed group
than the Always group (10.79 mm). The mean MSTSQ,
ISRs, and SF-MPQ during the safety-extension phase are
summarized in Additional file 1: Table S1.
Compliance and analgesic use
Treatment compliance during the comparative phase
was high: 64/65 (98.5%) patients receiving IFNβ-1a and
62/64 (96.9%) patients receiving IFNβ-1b adhered to
their medication schedule ≥90% of the time. Similarly, of
the patients enrolled in the safety-extension phase, 102/
116 (87.9%) were ≥90% compliant. Throughout the
study, analgesics were used by the majority of patients.
The percentage of patients using analgesics did not differ
greatly between groups in either phase of the study; dur-
ing the full-dose period of the safety population, anal-
gesic use in the IFNβ-1a and IFNβ-1b was 61.5% and57.8%, respectively, and mean total (SD) dose was 16,652
(16,941) mg and 12,862 (10,159) mg, respectively. Post-
injection analgesic use for the treatment of an ISR was
recorded by 1/64 patients in the IFNβ-1b group. During
the full dose period, concomitant analgesic use for treat-
ment of an ISR was recorded by 4/65 patients in the
IFNβ-1a group and by 1/64 patients in the IFNβ-1b
group. During the extension phase, analgesic use in the
Always IFNβ-1a group and Delayed IFNβ-1b group was
80.4% and 78.3%, respectively.
The most commonly used (>3 individuals) analgesics
during both study phases included ibuprofen, paraceta-
mol, naproxen, and acetylsalicylic acid.
Safety
AEs during the comparative phase
AEs reported in ≥5% of patients in either group during
the comparative phase are shown in Table 3. AEs that
were more common in the IFNβ-1a group than in the
IFNβ-1b group included ISRs, nausea, increased alanine
aminotransferase (ALT), increased serum ferritin, and
abnormal liver-function test. AEs that were more com-
mon in the IFNβ-1b group than in the IFNβ-1a group
included depression, fatigue, and dizziness. Most AEs
occurring during the comparative phase were mild to
moderate in severity. Severe AEs that occurred in at
least one patient in the IFNβ-1a group were influenza-
like illness (n = 2), back pain (n = 2), and headache
(n = 2). Severe AEs that occurred in at least one patient
in the IFNβ-1b group were back pain (n = 2) and head-
ache (n = 2). During the comparative phase, six patients
(all in the IFNβ-1a group) discontinued due to an AE.
Table 3 TEAEs reported by ≥5% of patients in either
group during the comparative phase (safety population)





Influenza-like illness 20 (30.8) 18 (28.1)
Headache 17 (26.2) 16 (25.0)
Injection-site reaction 18 (27.7) 9 (14.1)
Injection-site erythema 8 (12.3) 8 (12.5)
Depression 4 (6.2) 8 (12.5)
Fatigue 3 (4.6) 9 (14.1)
Urinary tract infection 7 (10.8) 5 (7.8)
Extremity pain 6 (9.2) 6 (9.4)
Nausea 7 (10.8) 3 (4.7)
Insomnia 5 (7.7) 5 (7.8)
Injection-site pain 4 (6.2) 5 (7.8)
Alanine aminotransferase increased 8 (12.3) 1 (1.6)
Back pain 4 (6.2) 4 (6.3)
Dizziness 2 (3.1) 6 (9.4)
Muscle spasms 5 (7.7) 3 (4.7)
Pain 4 (6.2) 3 (4.7)
Diarrhea 2 (3.1) 5 (7.8)
Chills 5 (7.7) 2 (3.1)
Influenza 5 (7.7) 2 (3.1)
Injection-site bruising 5 (7.7) 2 (3.1)
Serum ferritin increased 6 (9.2) 0
Liver-function test abnormal 5 (7.7) 0
IFN, interferon; TEAE, treatment-emergent adverse event.
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function tests (n = 2) and elevated liver function tests
plus the following: muscle cramps and spasms, chills,
and headache (n = 1); elevated ferritin (n = 1);
leukopenia and neutropenia plus ISR (n = 1); and preg-
nancy (n = 1).
Serious AEs were reported in two patients. One pa-
tient receiving IFNβ-1a had high ferritin levels and was
subsequently diagnosed with grade 3, stage 2, chronic
hepatitis; the investigator considered this event probably
related to the study medication. One patient receiving
IFNβ-1b had cholelithiasis, which required cholecys-
tectomy; this event was considered unrelated to the
study medication.
AEs during the safety-extension phase
Most AEs occurring during the extension phase were
mild to moderate in severity. AEs occurring in >5%
of patients are listed in Additional file 2: Table S2. Se-
vere AEs that occurred in the Always IFNβ-1a group
were non-study-related post-surgery pain (n = 1), toothextraction pain (n = 1) and headache (n = 2). Severe AEs
that occurred in at least one patient in the Delayed
IFNβ-1a group were influenza-like illness (n = 2), and
headache (n = 2). During the extension phase, 17
patients (eight patients in the Always IFNβ-1a group
and nine patients in the Delayed IFNβ-1a group) dis-
continued due to an AE.
Serious AEs were reported in three patients in the
Always IFNβ-1a group: one patient had an accidental
overdose of IFNβ-1a, one patient developed cholecystitis
(the same patient who had high ferritin and chronic
hepatitis in the comparative phase), and one patient
experienced vertigo. Serious AEs were reported in four
patients in the Delayed IFNβ-1a group: one patient
experienced intestinal obstruction, one patient experi-
enced diverticulitis, one patient had an accidental over-
dose of study drug, and one patient had a hip fracture.
Both cases of accidental overdose were due to misunder-
standing of the dosing regimen. The case of cholecystitis
was considered unlikely to be related to the study medi-
cation, and the other four serious AEs that occurred dur-
ing the extension phase were considered to be unrelated
to the study medication.
Other safety assessments
The mean values of hemoglobin, hematocrit, red blood
cell counts, platelet counts, white blood cell counts, and
alkaline phosphatase were within normal limits in each
arm throughout the entire study. In the IFNβ-1a group,
mean aspartate aminotransferase (AST) and ALT values
become elevated above normal limits during the com-
parative phase. Mean AST (normal range 0–35 U/L)
peaked at Week 8 (mean [SD] of 45.1 [40.4] U/L) but
returned within normal limits in the Always IFNβ-1a
group by Week 36. Mean ALT (normal range 4–36 U/L)
also peaked at Week 8 (mean [SD] of 71.6 [104.4] U/L)
and then declined, returning within normal limits in the
Always IFNβ-1a group by Week 48. In the IFNβ-1b
group, mean AST and ALT values initially increased
slightly from baseline and then became steady during
the comparative phase, but remained within normal lim-
its. In the extension phase, after transitioning to IFNβ-
1a, mean AST values remained within normal limits,
while mean ALT values rose above normal limits, peak-
ing at Week 24 (mean [SD] of 42.3 [27.2] U/L), but
returned within normal limits by Week 48.
The normal ranges for ferritin varied between the la-
boratories where the assay was performed. Analysis of
individual patient data showed that 26/65 (40.0%)
patients in the IFNβ-1a group and 12/64 (18.8%)
patients in the IFNβ-1b group had an elevated ferritin
value at any time during the comparative phase, with
ferritin levels considered to be transiently elevated in
two patients receiving IFNβ-1a and three patients
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patients in the Always IFNβ-1a group and 17/60 (28.3%)
patients in the Delayed IFNβ-1a group had elevated
ferritin at any time. Among these patients, ferritin was
considered transiently elevated in 13 patients in the Al-
ways IFNβ-1a group and six patients in the Delayed
IFNβ-1a group.
Relapse rate during treatment
At 12 weeks in the comparative phase, in the IFNβ-1a
group, eight patients (12.3%) reported one relapse, and
one patient (1.5%) reported two relapses. In the IFNβ-1b
group, seven patients (10.9%) reported one relapse. The
mean (SD) number of relapses per patient was signifi-
cantly higher in the IFNβ-1a group (0.15 [0.40]) versus
the IFNβ-1b group (0.11 [0.31]; p < 0.001).
In the extension phase, 14 patients (25.0%) in the Always
sc IFNβ-1a group had at least one relapse. Twelve patients
(20.0%) in the Delayed sc IFNβ-1a group reported at
least one relapse. The mean (SD) annualized number of
relapses was 0.28 (0.63) in the Always IFNβ-1a group and
0.56 (1.57) in the Delayed IFNβ-1a group; the difference
between groups was not statistically significant.
Discussion
This study was the first randomized clinical trial to com-
pare the injection-site pain and tolerability profile of the
serum-free formulation of IFNβ-1a with that of another
disease-modifying drug used in the treatment of MS.
Patients were allowed to manage their pain with anal-
gesic drugs. There was a tendency towards less pain
being reported in patients in the IFNβ-1a group who did
not use analgesics compared with the IFNβ-1b group. In
patients who did use analgesics, the dose of analgesics
for FLS and ISRs varied widely between patients over
both study phases, although mean total dose tended to
be higher in the IFNβ-1a group than in the IFNβ-1b and
Delayed IFNβ-1b groups. Overall, in the first 21 full
doses of IFNβ-1a and IFNβ-1b, mean increases in VAS
pain scores from before injection to all timepoints
after injection were not significantly different and small
(<5 mm) in both groups, indicating that sc injections
with both treatments were well tolerated for pain and
likely contributed to high patient compliance in both
treatment groups.
Over 96% of patients in either treatment group were
≥90% compliant with treatment during the comparative
phase. Similarly, 102/116 (87.9%) patients were ≥90%
compliant during the extension phase. The high rates of
long-term compliance suggest good tolerability with
both IFNβ-1a and IFNβ-1b, although compliance is usu-
ally greater in the clinical trial setting than in everyday
clinical practice, prompting the need for long-term real-
world-evidence studies.Differences between the treatment groups were also
not statistically significant for a number of other second-
ary assessments for pain. These included the mean
increase in VAS pain score at all three post-injection
timepoints, and the percentage of patients pain-free on
both the VAS diary and the SF-MPQ. The MSTSQ over-
all satisfaction, injection system, and background infor-
mation scores also did not differ significantly between
the treatment groups during the full-dose period of the
comparative phase. Overall, the results suggest that
the use of the new formulation of IFNβ-1a with auto-
injectors did not adversely affect tolerability outcomes
and user satisfaction any more than the commercially
available formulation of IFNβ-1b.
Rater-blinded assessment of ISRs were also not statis-
tically different between the groups, except in injection-
site bruising, which was significantly more common with
IFNβ-1a than with IFNβ-1b during the full-dose period,
and injection-site swelling, which was significantly more
common with IFNβ-1b than with IFNβ-1a during upti-
tration. The observed differences in these two para-
meters could be due to the different natures of the two
β-IFNs, the contents of the formulations, and mechanics
of the auto-injector devices. Determination of the plaus-
ible explanation would require further studies. Overall,
most patients (>80%) did not experience FLS or ISRs on
the MSTSQ during the comparative phase. Data on
which side effects within the definition of FLS caused
patients the most concern would be useful endpoints to
study in future studies.
While relapse rate at Week 12 of the comparative
phase was significantly higher for IFNβ-1a than for
IFNβ-1b, the clinical relevance of these subject-reported
relapses remains unclear. Importantly, the study was not
designed to compare efficacy objectively, so the results
of those analyses should be interpreted with caution.
However, overall treatment satisfaction did not differ
between patients treated with IFNβ-1a and those treated
with IFNβ-1b. Very low VAS pain scores from before
injection to all timepoints were also reflected in the
overall population of the safety-extension phase.
AEs reported during the comparative and safety-
extension phases were consistent with the known safety
profiles of IFNβ-1a and IFNβ-1b. Elevated serum ferritin
may be a useful biomarker for monitoring responses to
IFNβ treatment [18]; in this study, elevated serum ferritin
levels were observed in both groups, and more commonly
so in the IFNβ-1a group than in the IFNβ-1b group.
The high discontinuation rate observed during the
extension phase may be due to the occurrence of AEs
and/or the perceived commitment of remaining in the
study, when there was availability of the original formu-
lation commercially, and where a treatment switch was
inevitable at study termination.
Singer et al. BMC Neurology 2012, 12:154 Page 10 of 11
http://www.biomedcentral.com/1471-2377/12/154A number of previous studies compared the side-effect
profile of the original IFNβ-1a with that of IFNβ-1b in
patients with MS [8,19-21]. In a small, non-randomized
exploratory study of 20 patients, mean increases in
VAS pain scores from before injection to immediately,
10 min, and 60 min after injection were greater in
patients receiving IFNβ-1a 44 μg sc tiw than in patients
receiving IFNβ-1b 250 μg sc qod [19], although com-
parisons between groups were not tested for statistical
significance. In a larger randomized study of 301
patients with RRMS, treatment with either the original
formulation of IFNβ-1a 22 μg sc once a week or IFNβ-
1b 250 μg sc qod did not show any significant dif-
ferences between the treatment groups in the rates of
FLS or skin reactions [20]. In an observational cohort
study of 445 patients with RRMS, a greater percentage
of patients receiving IFNβ-1b 250 μg sc qod were pain-
free over 15 full-dose injections immediately, 30 min,
and 60 min after injection compared with patients
receiving the original IFNβ-1a 44 μg sc tiw [21]. How-
ever, the study was not randomized or controlled. Injec-
tion of IFNβ-1a at room temperature to reduce possible
sensation of cold burning as per the manufacturer’s
recommendations for use was also assumed. In another
observational cohort study, the percentage of patients
reporting an ISR did not differ significantly between
those receiving the original IFNβ-1a and those receiving
IFNβ-1b [8], lending evidence to a mild, variable toler-
ability between sc preparations of IFNβ-1b and IFNβ-1a.
The serum-free formulation of IFNβ-1a was evaluated
with the aim of improving local tolerability to injection.
An additional potential benefit is reduced immunogen-
icity; following independent observations in a 96-week
study, a lower prevalence of neutralizing antibodies was
observed in patients receiving the serum-free formula-
tion of IFNβ-1a, as compared with patients treated with
the original IFNβ-1a [9,10]. However, in this present
study, no data were collected on the development of
neutralizing antibodies to IFNβ-1a to allow comparison
with the above study findings.
Limitations of the study
Injection depth may affect pain and ISRs, although the
various injection depth options that patients used were
not recorded. This study mirrored general-practice use
of auto-injectors, whereby patients choose their individ-
ual depth setting.
The utilization of VAS pain scores at smaller-ranging
scales, for instance, from 0 to 10 mm, may have been
more useful in obtaining a more sensitive picture of
injection-site pain with these therapies. Also, except for
inspection of injection-site redness, the study was not
blinded. Lack of patient blinding may have influenced
some of the patient-rated measures such as ratings ofrelapse, pain, and FLS. The clinical relevance of patient-
reported relapse data is unclear and so, with the lack
of objective assessment of relapses, results of those ana-
lyses should be interpreted with caution. In the statistical
analyses of patient-rated measures, no adjustments for
multiple comparisons were made. Although a limitation,
no statistically significant differences across groups on
any of the patient-rated assessments were observed, sug-
gesting that this aspect of the study design was not a ser-
ious weakness of the study. However, to ensure certainty
in any future analyses, the blinding of patients is recom-
mended to reduce any potential of bias in the patient-
rated measures.
Although the safety-extension phase was useful in
gaining data on longer-term tolerability to IFNβ-1a,
large dropouts and confounding variables such as treat-
ment switch from a high dose of IFNβ-1b to IFNβ-1a
did not permit systematic analyses from which valid
interpretations and conclusions could be made.Conclusions
The results from this study in IFNβ-treatment-naïve
patients with RRMS regarding tolerability and safety of
the serum-free formulation of IFNβ-1a and IFNβ-1b
demonstrate that these treatments are accompanied by
comparable and low levels of injection-site pain.Additional files
Additional file 1: Table S1. Mean MSTSQ, ISR, and SF-MPQ during the
safety-extension phase.
Additional file 2: Table S2. Adverse events reported by ≥5% of all
patients during the safety-extension phase.Competing interests
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